Marshall Wace’s Generation Bio GBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-140,294
| Closed | -$797K | – | 3384 |
|
|
2025
Q4 | $797K | Sell |
140,294
-78,167
| -36% | -$442K | ﹤0.01% | 2043 |
|
|
2025
Q3 | $1.34M | Buy |
218,461
+206,841
| +1,780% | +$1.07M | ﹤0.01% | 1812 |
|
|
2025
Q2 | $37.2K | Buy |
+11,620
| New | +$44.8K | ﹤0.01% | 2616 |
|
|
2024
Q1 | – | Sell |
-12,359
| Closed | -$204K | – | 2571 |
|
|
2023
Q4 | $204K | Buy |
12,359
+8,912
| +259% | +$155K | ﹤0.01% | 1974 |
|
|
2023
Q3 | $131K | Hold |
3,447
| – | – | ﹤0.01% | 2031 |
|
|
2023
Q2 | $190K | Hold |
3,447
| – | – | ﹤0.01% | 2250 |
|
|
2023
Q1 | $148K | Hold |
3,447
| – | – | ﹤0.01% | 2448 |
|
|
2022
Q4 | $135K | Buy |
3,447
+65
| +2% | +$3.41K | ﹤0.01% | 2759 |
|
|
2022
Q3 | $180K | Sell |
3,382
-65
| -2% | -$4.07K | ﹤0.01% | 3107 |
|
|
2022
Q2 | $226K | Hold |
3,447
| – | – | ﹤0.01% | 3133 |
|
|
2022
Q1 | $253K | Sell |
3,447
-2,000
| -37% | -$116K | ﹤0.01% | 3017 |
|
|
2021
Q4 | $385K | Buy |
5,447
+1,726
| +46% | +$301K | ﹤0.01% | 2935 |
|
|
2021
Q3 | $933K | Sell |
3,721
-7,412
| -67% | -$1.77M | ﹤0.01% | 2064 |
|
|
2021
Q2 | $3M | Buy |
+11,133
| New | +$3.33M | 0.01% | 1147 |
|
Other funds holding GBIO
Marshall Wace's GBIO Position: Q1 2026 in Review
Marshall Wace sold out of Generation Bio (GBIO) in Q1 2026, closing a stake of 140,294 shares — an estimated $797K sold.
Marshall Wace first reported a position in GBIO in Q2 2021 and held it in 14 quarters. The position peaked at $3M in Q2 2021. 2 funds tracked by Wall St. Rank hold GBIO as of Q1 2026.
- Marshall Wace reported no remaining Generation Bio position as of Q1 2026 after selling out during the quarter.
- Marshall Wace sold 140,294 Generation Bio shares in Q1 2026, an estimated $797K.
- Marshall Wace first reported a position in Generation Bio in Q2 2021 and held it in 14 quarters.
- Marshall Wace's Generation Bio position peaked at $3M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Generation Bio as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.